VIELA BIO, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
VIELA BIO, INC. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$150.67 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2021-03-01
- VIELA BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was -$33.39M.
- VIELA BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$37.65M.
- VIELA BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$38.86M.
- VIELA BIO, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$40.78M.
- VIELA BIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$150.67M.
- VIELA BIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$86.43M.
- VIELA BIO, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$190.27M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$33.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$71.03M derived: sum of 2 quarters · filed 2021-03-01 | -$109.89M derived: sum of 3 quarters · filed 2021-03-01 | -$150.67M 10-K · filed 2021-03-01 |
| 2020-09-30 | -$37.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$76.50M derived: sum of 2 quarters · filed 2020-11-10 | -$117.28M 10-Q · filed 2020-11-10 | -$128.85M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | -$38.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$79.63M 10-Q · filed 2020-08-12 | -$91.20M derived: sum of 3 quarters · filed 2021-03-01 | -$139.61M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-03-31 | -$40.78M 10-Q · filed 2020-05-13 | -$52.35M derived: sum of 2 quarters · filed 2021-03-01 | -$100.76M derived: sum of 3 quarters · filed 2021-03-01 | -$106.23M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-12-31 | -$11.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$59.98M derived: sum of 2 quarters · filed 2021-03-01 | -$65.45M derived: sum of 3 quarters · filed 2021-03-01 | -$86.43M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$48.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$53.88M derived: sum of 2 quarters · filed 2020-11-10 | -$74.86M 10-Q · filed 2020-11-10 | -$89.91M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$5.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$26.45M 10-Q · filed 2020-08-12 | -$41.50M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2019-03-31 | -$20.98M 10-Q · filed 2020-05-13 | -$36.03M derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2018-12-31 | -$15.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$190.27M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | -$175.22M 10-Q · filed 2019-11-14 |